Please login to the form below

Sangamo

This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Sangamo’s zinc finger protein transcription factor (ZFP-TF) approach involves introducing double-stranded DNA breaks engineered to target specific sequences in a cell. ... Sangamo also has a gene therapy platform, with a first candidate for haemophilia

Latest news

Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price

This includes Sangamo and Pfizer, whose gene therapy achieved a dose-dependent increase in clotting Factor VIII levels across four dosage groups, each including two subjects.
UK’s CMA clears Roche’s $4.3bn takeover of Spark

Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
Sangamo steps up BioMarin chase with haemophilia gene therapy data

Updated results presented at ASH 2019. Sangamo has been playing catch-up with BioMarin in the race to develop a gene therapy for haemophilia A, but new data reported at the ... Sangamo is adamant that it is still in contention in the haemophilia A gene
Roche moving closer to approval of Spark takeover; report

number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
Pfizer goes big on gene therapy with $500m facility spend

That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a

More from news
Approximately 10 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Alzheimer’s: the search for a cure

gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance.
Bluebird: on a mission to ‘recode’ the DNA of healthcare

The success or failure of Bluebird will be closely watched by a slew of cell and gene therapy companies including Sangamo, BioMarin (with exciting potential cures for haemophilia) and UniQure, looking
2019: CRISPR and therapeutic gene editing comes of age

Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers to take the slow road to proving that gene- editing can deliver safe and effective
The handover: Pfizer reshapes itself for a new era

It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.
Deal Watch table for January 2014

320. Sangamo/Biogen Idec . Collaboration and licence. Development of therapies for haemoglobinopathies using zinc finger genome editing.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Eric Rhodes becomes CEO of ERS Genomics

Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...